What are the latest funding trends in femtech?

All funding deals in the femtech market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the Femtech Market.

Is Femtech funding actually up right now?

Femtech funding is up sharply in dollars today, but the number of startups getting funded is still going down.

We tracked 44 financings across 43 companies in the current period, compared with 52 deals across 50 companies over the same stretch of 2025. That puts deal activity down 15% year over year and funded-company count down 14%.

The capital picture looks much stronger. After cross-checking material round amounts against first-hand announcements and correcting clear discrepancies, we calculate roughly $392 million of usable 2026 capital, versus about $231 million in the comparable 2025 period.

That is an increase of roughly 70%.

But two enormous rounds explain most of the difference. Midi Health raised $100 million and Pomelo Care raised $92 million. Remove financings above $50 million and 2026 falls to roughly $200 million, about 13% below last year's comparable figure.

So yes, a lot more money has gone into Femtech this year. For the average founder looking around the market, though, fundraising has not suddenly become easier. Fewer companies are closing rounds, and nearly half of this year's capital sits in two transactions.

One caution is especially important for 2024. Flo Health disclosed its financing only as more than $200 million, so we did not invent an exact amount for it. The $378.6 million shown below is therefore only the usable exact-amount subtotal; known lower bounds already put the real comparable-period figure above roughly $609 million.

Market measure	2026 YTD	2025 YTD	2024 YTD	2026 vs 2025
Deals	44	52	55	-15.4%
Unique companies	43	50	54	-14.0%
Usable capital	≈$392M	$231.0M	$378.6M exact subtotal	≈+70%
Capital excluding >$50M rounds	≈$200M	$231.0M	$278.6M exact subtotal	≈-13%
Largest observed round	$100M	$18M	>$200M	Much larger YoY
Rounds above $50M	2	0	2	+2
First financings	10	12	7	-16.7%
Early-stage deal share	70.5%	71.2%	63.6%	-0.7pp
Later-stage deal share	11.4%	7.7%	18.2%	+3.7pp

Are Midi Health and Pomelo Care making Femtech funding look stronger than it really is?

Yes. Midi Health and Pomelo Care alone account for almost half of the Femtech capital we tracked this year.

Midi raised $100 million in a Series D led by Goodwater Capital. Pomelo Care raised $92 million in its Series C led by Stripes. Together, the two deals represent roughly $192 million, or 49% of current usable capital.

Both companies were already well beyond the normal startup-validation stage. Midi had built a large menopause and perimenopause care business before expanding toward broader women's healthcare, while Pomelo had already built a national maternity-care platform and said its model covered nearly 7% of US births when it announced the financing.

That explains a lot of the gap between the headline total and the rest of the market.

The concentration goes further than those two rounds. Add Rejoni's $25 million financing, ONTO Health's $20 million Series A and OncoRes Medical's roughly US$19 million equivalent round, and the five largest financings account for around 65% of all the money we tracked.

Last year had no comparable $50 million-plus deal in the same period.

These days, there is clearly serious capital available for a small group of Femtech companies that have scale, clinical evidence, a strong regulatory path or a commercially proven model. That is a much narrower claim than saying money is plentiful across Femtech.

Are more Femtech startups actually getting funded in 2026?

No. The Femtech market currently has fewer funded companies than it did in either of the previous two comparable periods.

We counted 43 unique companies this year, down from 50 in 2025 and 54 in 2024. Deal count moved in almost the same direction, from 55 to 52 to 44.

The extra dollars therefore did not come from capital spreading across a larger population of startups.

There is also very little duplication hidden inside the 44 transactions. Only one company completed more than one financing during the comparable 2026 period.

The market has become more capital-heavy without becoming broader. There are fewer funded names, while a handful of companies are raising dramatically larger amounts.

For founders, that distinction is probably more useful than the aggregate dollar total.

Is Series A getting harder for Femtech startups?

Yes. Series A is one of the clearest weak spots in Femtech fundraising right now.

We found eight Series A financings this year, compared with 14 during the same period in 2025. That is a 43% drop in deal count.

There are still substantial Series A rounds. ONTO Health raised $20 million to expand its fertility and longevity model in the US and Gulf region. BrightHeart raised €11 million to scale its AI platform for prenatal ultrasound. SimpliFed closed a $10.8 million Series A to expand its maternal-care platform, while Dioseve raised roughly $7 million in an extension financing around its IVF technology.

The problem is the number of companies reaching that point.

Seed still produces plenty of transactions, and the market now has a few businesses capable of raising $50 million to $100 million. The bridge between those two ends looks thinner.

That makes the current market especially awkward for a company that has already raised Seed capital but still needs to prove enough clinical, commercial or reimbursement traction for its next institutional round. The weak spots shared by startups that stall before their next round are compared in our report covering the femtech market.

Is Femtech becoming a later-stage funding market?

Femtech is still an early-stage market by deal count, while the dollars increasingly make it look like a later-stage one.

About 70% of this year's transactions are Seed or Series A, essentially unchanged from last year. Seed alone accounts for more than half of all deals.

Yet two mature financings absorb almost half of current capital: Midi's Series D and Pomelo's Series C.

That split is why simple funding totals are particularly misleading here. Transaction count still describes an early-stage ecosystem, while the capital total is being pulled upward by a small upper tier.

The important development today is that a few companies have reached a completely different financing scale while most of the transaction base remains early.

Stage	2026 deals	Deal share	Notable 2026 examples
Seed	23	52.3%	Clair, iPremom, DITTO
Series A	8	18.2%	ONTO Health, BrightHeart, SimpliFed
Series B	3	6.8%	May Health, Nadia Care
Series C	1	2.3%	Pomelo Care
Series D+	1	2.3%	Midi Health
Growth Equity	0	0%	None
Unknown stage	8	18.2%	OncoRes, ScreenPoint, Rejoni
Early stage overall	31	70.5%	Seed + Series A

Are new Femtech startups getting squeezed out?

New Femtech startups can still raise money, but we are not seeing a new wave of companies entering the funded market.

We identified 10 first financings this year, compared with 12 over the same period in 2025. Their share of all deals barely changed because the whole market also got smaller.

Several newcomers did raise meaningful rounds. iPremom closed a €15 million Seed round for its pregnancy-complication diagnostics platform. Clair raised $11.6 million for its women's hormone-monitoring wearable. ONTO Health appears in our financing-history work as a first financing and raised $20 million.

American Baby Company also entered the market with a $4 million Seed round around a lower-cost IVF clinic model.

Those examples show that new companies are still getting backed when investors see a strong enough wedge.

What we do not see is broader startup formation. The number of first financings went down, and the overall number of funded companies fell with it.

The current market looks selective rather than closed.

Is fertility still the hottest part of Femtech funding?

No. Fertility has cooled dramatically from its unusually strong 2025.

Fertility Care represented 34.6% of deals last year. Today that share is 15.9%, a fall of almost 19 percentage points.

The dollar decline is also substantial even after correcting several individual deal amounts. We calculate roughly $43 million across Fertility Care in the current period, or about 11% of total usable capital. The category represented almost half of usable capital in the comparable 2025 period.

The current deal flow is hardly dead. ONTO Health raised $20 million, Dioseve closed roughly $7 million, American Baby Company raised $4 million, and May Health raised €10 million for a PCOS-related infertility treatment.

The two-year comparison makes the picture clearer. Fertility accounted for 18.2% of deals in 2024, then jumped to 34.6% in 2025 before falling to 15.9% now.

That looks much more like a 2025 spike than the beginning of a permanent shift toward fertility. Telling a one-year spike from lasting demand starts with a size estimate built from the ground up, as in our report on femtech.

Is Pregnancy Care becoming the strongest part of Femtech funding?

Yes. Pregnancy Care currently has the best combination of deal breadth and serious capital in Femtech.

We tracked 10 Pregnancy Care financings, giving the category 22.7% of all deals. After refreshing the major financing amounts, we calculate roughly $152 million of usable capital, close to 39% of the market.

Pomelo Care is the biggest reason for the dollar jump with its $92 million Series C, but the category does not depend on Pomelo alone.

iPremom raised €15 million to take its molecular pregnancy diagnostics toward clinical validation and commercial rollout. BrightHeart raised €11 million around AI for prenatal ultrasound. Nadia Care closed $12 million to expand its community-based maternal care model. SimpliFed added $10.8 million for virtual perinatal services.

Oli Medical also raised A$6.5 million for its maternal and fetal monitoring platform.

That is a much deeper group than we see in Hormonal Health, where one company dominates almost all of the large-dollar activity.

Pregnancy Care was already a major part of Femtech in 2024, so this is better described as a strong rebound and scale-up year than the sudden creation of a new category.

Femtech category	2026 deals	Deal share	Approx. usable capital	Approx. capital share
Pregnancy Care Solutions	10	22.7%	≈$152M	≈38.6%
Hormonal Health Platforms	4	9.1%	≈$113M	≈28.7%
Women's Primary Care	11	25.0%	≈$44M	≈11.2%
Fertility Care Platforms	7	15.9%	≈$43M	≈10.9%
Pelvic Care Devices	6	13.6%	≈$29M	≈7.4%
Menstrual Health Tools	6	13.6%	≈$12M	≈3.2%
Total	44	100%	≈$392M	100%

Is Hormonal Health really booming in Femtech?

Hormonal Health has a lot of money behind it right now, but almost all of the scale comes from Midi Health.

We calculate roughly $113 million of usable capital in the category. Midi contributes $100 million of that amount.

Clair is the other major financing, with an $11.6 million Seed round for a wearable designed around female hormone monitoring. Coral and Osteoboost account for much smaller transactions.

The category therefore has an interesting upper end without much deal breadth. Only four Hormonal Health financings appear in our current period, fewer than Pregnancy, Primary Care, Fertility, Menstrual Health or Pelvic Care.

Midi itself also makes the category harder to interpret. The company built its early position around menopause and perimenopause care, but its latest financing is explicitly being used to expand into a broader women's healthcare platform spanning multiple life stages.

Calling all $100 million a pure bet on hormonal health would therefore oversimplify what the company has become.

As seen above, investors are clearly willing to fund large women's-health platforms. We have much less evidence that they are suddenly writing giant checks across the whole hormonal-health category.

Why are so many Women's Primary Care deals actually diagnostics companies?

Women's Primary Care looks unusually busy because our category captures a growing group of breast, ovarian and other specialist diagnostics businesses alongside broader care platforms.

We counted 11 deals, the highest number of any category this year.

OncoRes Medical is one of the clearest examples. The Australian company raised A$27 million, roughly US$19 million, to move its breast-surgery imaging system through clinical development and regulatory milestones. Diagnostics still in clinical development are the kind of technology we sort into working, being tested or on paper in our femtech market report.

ScreenPoint Medical raised $14 million of equity, alongside $2 million of research grants that we exclude from the venture total. Its Transpara breast-imaging AI was already deployed in more than 30 countries and had processed over 12 million mammograms when the financing was announced.

ProSeek Bio raised A$1.5 million to advance an ovarian-cancer diagnostic test. Feminai also sits in breast diagnostics, while June Health represents a very different model built around women's healthcare navigation and clinical support.

That mix is why the label needs some interpretation. Women's Primary Care gaining deal share does not mean investors suddenly funded 11 conventional women's clinics.

A meaningful part of the activity is coming from diagnostic technology, imaging and specialist clinical infrastructure.

Is breast cancer technology becoming a serious Femtech investment category?

Yes. Breast diagnostics and surgical technology are now too visible in the Femtech deal flow to treat them as edge cases.

OncoRes and ScreenPoint alone account for more than $30 million of equity financing in our current period.

The companies are also beyond the concept stage in very different ways. OncoRes is using its financing for clinical development and regulatory milestones around an intraoperative imaging system designed to help surgeons identify cancerous tissue during breast-conserving surgery.

ScreenPoint is further into commercial deployment. Its breast-imaging AI is already used internationally, including within major screening programs and healthcare systems.

This fits a much broader capital pattern. The World Economic Forum's 2026 Women's Health Investment Outlook found that roughly 90% of private investment identified in women's health still flows to three areas: women's cancers, reproductive health and maternal health.

That outside evidence does not explain any individual deal, but it does fit what we are seeing now. Investors are more comfortable putting meaningful capital behind areas with large patient populations, established clinical pathways and clearer economic value.

Are strategic investors becoming much more active in Femtech?

Yes. Strategic-investor participation is one of the clearest broad improvements in Femtech this year.

We found strategic investors in 12 of 44 deals, or 27.3% of all transactions. The comparable figure last year was 15.4%.

This is spread across several parts of the market.

Siemens Healthineers participated in ScreenPoint Medical, whose AI works directly within breast-imaging workflows. Securian Canada invested strategically in June Health, which distributes women's healthcare through employers and partners. Shionogi and the Asuka-linked fund joined Dioseve's fertility financing. Ascension Ventures participated in Rejoni's $25 million round.

The strategic activity also cuts across company maturity. We see participation in Seed, Series A, Series B and later-stage transactions.

That breadth is more interesting than a single corporate-backed megadeal would have been.

Currently, healthcare companies, insurers and health-system investors appear increasingly willing to put capital directly into women's-health infrastructure that touches their existing clinical or commercial businesses.

Strategic-capital measure	2026	2025	2024
Deals with strategic participation	12	8	11
Share of all deals	27.3%	15.4%	20.0%
YoY change in share	+11.9pp	-	-
Fertility deals with strategic participation in 2026	5	-	-
Women's Primary Care deals with strategic participation in 2026	4	-	-
Seed deals with strategic participation in 2026	4	-	-
Series A deals with strategic participation in 2026	3	-	-
Series B deals with strategic participation in 2026	2	-	-
Series D+ deals with strategic participation in 2026	1	-	-

Is Femtech funding becoming more global?

Yes, especially by deal count, although North America still captures most of the biggest checks.

Asia-Pacific represents 18.2% of current deals, up from 9.6% last year. The absolute number increased from five to eight.

Australia is particularly visible. OncoRes raised A$27 million, Oli Medical raised A$6.5 million, Ovum raised A$4 million and ProSeek Bio raised A$1.5 million.

Japan adds Dioseve's fertility financing, while India appears through Pinky Promise and Avni.

Europe remains a major part of the market as well. BrightHeart, iPremom, DITTO, ScreenPoint and several smaller companies all raised capital there this year.

North America still accounts for half of all deals, and the two largest transactions, Midi and Pomelo, are US companies. So this is not a geographic handover.

The deal base is gradually widening outside North America even while the biggest capital pools remain heavily US-centered. What investors back as deals spread beyond North America, and what they now avoid, is examined in our market report about femtech.

Are Femtech investors becoming more selective about which companies they back?

Yes. The companies reaching larger Femtech rounds now tend to look more proven, and current investor commentary points in the same direction.

The median company age at financing increased from four years to five years. The shift becomes more obvious further up the ladder: the median Series A recipient in our research is 6.5 years old, versus 3.5 years last year, while Series B moved from six years to nine.

That does not mean investors simply prefer older companies. Age is more likely acting as a rough proxy for what companies have had time to build.

The current funding examples fit that interpretation. Pomelo could point to measurable maternity outcomes and national payer scale. ScreenPoint already had international commercial deployment. OncoRes was financing clinical and regulatory work. Rejoni is pushing toward FDA approval and launch. Materna is financing pivotal-trial, manufacturing and commercialization milestones.

A recent Morgan Lewis review of women's-health investing also focused heavily on clinical evidence, regulatory pathways, reimbursement, real-world data and commercially meaningful endpoints when describing what investors and strategic partners now need to diligence.

For now, the market seems willing to pay up when those pieces are in place. Getting to that level of proof appears harder.

Has 2026 already beaten all of 2025 for Femtech funding?

Yes in dollars. By deal count, 2026 is still far behind.

We calculate roughly $392 million of usable capital in the current period after the fresh verification pass. Full-year 2025 produced about $296 million in our comparable dataset.

So 2026 has already exceeded last year's full-year usable capital by roughly one-third.

At the same time, the current 44 deals represent only about 68% of the 65 financings recorded across the whole of 2025.

That is probably the cleanest illustration of what has changed: a much larger amount of money has moved through substantially fewer transactions.

We would not annualize the current pace. Venture financings arrive unevenly, and one large late-year deal could change the picture again.

The historical comparison also keeps the excitement in check. 2024 included Flo Health's financing of more than $200 million plus Amber Therapeutics' $100 million round. Even without pretending we know Flo's exact amount, the identifiable 2024 comparable-period lower bound is already above roughly $609 million.

So 2026 is a very capital-heavy year, especially versus 2025, but Femtech has seen extreme concentration before.

Does the wider women's-health funding story look as strong as the Femtech headlines suggest?

The wider women's-health market is attracting more serious investor attention, but the money is still concentrated in a relatively small number of conditions and companies.

Silicon Valley Bank's 2026 women's-health report says about $2 billion of venture capital went into women's health across the US and Europe in 2025 and sees signs of a rebound in 2026.

That research uses a broader market definition than ours, so the totals should not be compared directly. Because women's health can be drawn narrowly or broadly, we spell out what counts as femtech, and what doesn't, in our report on femtech.

The direction is still useful. Women's health is increasingly being treated as a serious healthcare investment category rather than a small lifestyle niche.

The World Economic Forum reaches a similar conclusion from another angle. Its 2026 investment work found that women's health receives only around 6% of private healthcare investment and that about 90% of that money is concentrated in women's cancers, reproductive health and maternal health.

Our current Femtech deal flow looks surprisingly similar to that picture. Pregnancy Care is the strongest broad category, fertility remains important despite its slowdown, and breast diagnostics are becoming a visible source of larger clinical-technology rounds.

The current opportunity is real. The capital is nowhere near evenly distributed.

What is actually changing in Femtech funding right now?

Femtech has become a much bigger funding market in dollars this year while simultaneously shrinking in the number of companies and deals receiving that money. The headline growth is real, but the benefits are highly concentrated.

Midi Health and Pomelo Care are central to the story. Their combined $192 million represents almost half of current capital, and the five largest rounds absorb roughly two-thirds of the market. Capital below the $50 million level is still lower than it was over the comparable 2025 period.

Pregnancy Care currently has the strongest broad momentum. It combines 10 financings with multiple eight-figure rounds across virtual care, diagnostics, prenatal AI and maternal-health infrastructure. Hormonal Health has plenty of capital too, although Midi accounts for nearly all of its scale.

Fertility has cooled sharply after an exceptional 2025 rather than disappearing as an investable category. Women's Primary Care is moving in another direction: more companies are getting funded, with a meaningful share of that activity coming from cancer diagnostics and imaging.

The funding ladder also looks tougher in the middle. Series A deal count has fallen from 14 to eight, while the companies that do attract bigger rounds increasingly arrive with clinical evidence, payer traction, regulatory progress or existing commercial deployment.

Strategic participation stands out as one of the healthier changes. Healthcare companies, insurers and health-system investors now appear in more than a quarter of deals, across several categories and stages.

Taken together, Femtech today looks richer at the top and more selective underneath. The market has clearly shown that it can produce $20 million, $90 million and $100 million financings. What it has not shown this year is that capital access is improving for the broader startup population.